EU Takes Dispute With Turkey On Localization Policy To Next Level
After unsuccessful negotiations with Turkey on its discriminatory policies against foreign drug producers, the EU has asked the World Trade Organization to set up a dispute settlement panel to resolve the matter.
You may also be interested in...
Localization Barriers To Trade In Medicines And Health Care Products: The Tricky Business Of Balancing Competing Interests
There is a clear tension at a global level between the need for the international movement of pharmaceutical products and the need for access to affordable medicines to support a sustainable health care system. Lincoln Tsang examines the global environment and suggests it is something that the British medicines and health care products industries will need to bear in mind when considering the prospect of the UK leaving the EU under WTO terms, as some are advocating.
The EU has filed a complaint at the WTO against Turkey’s localization policy, which forces multinational pharmaceutical companies to produce medicines in Turkey. Industry sources say the EU may not get what it wants.
EU reviewers have recommended five new medicines and a pneumococcal vaccine for EU-wide approval. New uses of several approved medicines have also drawn the thumbs up, while the sponsor of a cancer drug has withdrawn its product from the review process.